EDWARD L. AMOROSI, M.D.; SIMON KARPATKIN, M.D.
This content is PDF only. Please click on the PDF icon to access.
In the 50 years since its first description (1), some aspects of the pathogenesis of thrombotic thrombocytopenic purpura have been clarified, but its etiologic definition and the development of effective therapy have remained elusive tasks. Instances of its occurrence in siblings (2) or marital partners (3) and its response in one case to hemodialysis (4) have suggested an environmental causative agent(s) (viral, bacterial, antigenic, or toxic) interacting with a genetically predisposed host. Various therapeutic regimens have been applied including adrenocorticosteriods and splenectomy (5, 6), heparin (7), exchange transfusion (8), and antiplatelet agents (9-23) (aspirin, dipyridamole, sulfinpyrazone, and dextran), but definitive
AMOROSI EL, KARPATKIN S. Antiplatelet Treatment of Thrombotic Thrombocytopenic Purpura. Ann Intern Med. 1977;86:102–106. doi: https://doi.org/10.7326/0003-4819-86-1-102
Download citation file:
Published: Ann Intern Med. 1977;86(1):102-106.
Coagulopathies, Hematology/Oncology, Platelet Disorders.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use